Sign In
Buy ABUS
$4.34
-0.0700 (-1.59%)
At Close: Jul 31, 2026
Arbutus Biopharma clinical hold slows hepatitis B momentum: broker
02:44pm, Wednesday, 26'th Apr 2023
Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that its investigational new drug application for its n
Why Arbutus Biopharma Stock Is Sinking Today
11:50am, Tuesday, 25'th Apr 2023
The FDA has placed a clinical hold on AB-101, Arbutus' experimental chronic hepatitis B virus therapy. Arbutus had hoped to advance AB-101 into early-stage testing and report initial data on it later
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
07:30am, Thursday, 20'th Apr 2023
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
04:01pm, Tuesday, 18'th Apr 2023
Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical compa
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
07:30am, Thursday, 16'th Feb 2023
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Participate in Three Upcoming Investor Conferences
07:30am, Monday, 06'th Feb 2023
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call Transcript
10:42am, Wednesday, 09'th Nov 2022
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - Presi
Arbutus to Present at Jefferies London Healthcare Conference
07:30am, Tuesday, 08'th Nov 2022
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Present at Chardan's 6th Annual Genetic Medicines Conference
07:30am, Thursday, 22'nd Sep 2022
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call Transcript
03:06pm, Thursday, 04'th Aug 2022
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2022 Earnings Conference Call August 4, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - Presid
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
07:30am, Thursday, 21'st Jul 2022
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
03:36pm, Wednesday, 29'th Jun 2022
Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a tripl
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
03:54pm, Tuesday, 28'th Jun 2022
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
02:30pm, Wednesday, 08'th Jun 2022
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
02:05am, Wednesday, 08'th Jun 2022
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET
